Search - tctmd.com

Displaying 281 - 300 of 367

Sort: Relevancy | Date

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

News Features

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

October 08, 2021

TCTMD’s Top 10 Most Popular Stories for September 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for September 2021

October 01, 2021

Big Impact Anticipated With HFpEF Expansion of Sacubitril/Valsartan Label

News Daily News

Big Impact Anticipated With HFpEF Expansion of Sacubitril/Valsartan Label

September 20, 2021

In HF and Diabetes, Mobile Health App Modestly Boosts Physical Activity

News Daily News HFSA 2021

In HF and Diabetes, Mobile Health App Modestly Boosts Physical Activity

Michael O'Riordan

September 15, 2021

Digital App Improves HF Quality-of-Care Metrics: CONNECT-AF

News Conference News HFSA 2021

Digital App Improves HF Quality-of-Care Metrics: CONNECT-AF

Michael O'Riordan

September 14, 2021

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

News Conference News HFSA 2021

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

September 13, 2021

In HFrEF, AI Shows Promise For Predicting Beta Blocker Response

News Conference News ESC 2021

In HFrEF, AI Shows Promise For Predicting Beta Blocker Response

Yael L. Maxwell

September 03, 2021

New ESC HF Guidelines Showcase SGLT2 Inhibitors, Tafamidis, Vericiguat, and COAPT

News Conference News ESC 2021

New ESC HF Guidelines Showcase SGLT2 Inhibitors, Tafamidis, Vericiguat, and COAPT

August 28, 2021

EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF

News Conference News ESC 2021

EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF

August 27, 2021

FDA Green-lights Empagliflozin for HF With Reduced Ejection Fraction

News Daily News

FDA Green-lights Empagliflozin for HF With Reduced Ejection Fraction

Michael O'Riordan

August 19, 2021

July/August 2021 News Roundup

News Opinion CV Team Dispatch

July/August 2021 News Roundup

August 01, 2021

Who Are the Ideal Patients for an IASD: HFpEF, HFrEF, RCM, and Beyond…

Presentation TVT 2021

Who Are the Ideal Patients for an IASD: HFpEF, HFrEF, RCM, and Beyond…

Presenter: Sanjiv J. Shah

July 22, 2021

Beta-blocker Withdrawal Boosts Peak VO2 in HFpEF Subset: PRESERVE-HR

News Conference News ESC Heart Failure 2021

Beta-blocker Withdrawal Boosts Peak VO2 in HFpEF Subset: PRESERVE-HR

July 06, 2021

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

News Daily News

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

July 06, 2021

IRON-CRT: IV Iron Boosts LVEF, Cardiac Contractility in Deficient HF Patients

News Conference News ESC Heart Failure 2021

IRON-CRT: IV Iron Boosts LVEF, Cardiac Contractility in Deficient HF Patients

June 30, 2021

Moderate Aortic Stenosis and HFrEF Combo Portends Poor Survival, Study Finds

News Daily News

Moderate Aortic Stenosis and HFrEF Combo Portends Poor Survival, Study Finds

June 03, 2021

Dapagliflozin US Cost-effectiveness Data Expose Barriers to HF Care

News Daily News

Dapagliflozin US Cost-effectiveness Data Expose Barriers to HF Care

May 27, 2021

Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs

News Conference News ACC 2021

Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs

May 18, 2021

Effect of a Hospital and Post-discharge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction

Presentation ACC 2021

Effect of a Hospital and Post-discharge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction

Presenter: Adam DeVore

May 17, 2021

Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF

News Conference News ACC 2021

Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF

Yael L. Maxwell

May 16, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.